Gain Therapeutics’ (GANX) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report published on Tuesday morning, Benzinga reports. Oppenheimer currently has a $9.00 target price on the stock.

GANX has been the topic of several other reports. HC Wainwright reissued a buy rating and set a $9.00 target price on shares of Gain Therapeutics in a research note on Monday, April 1st. Chardan Capital reiterated a buy rating and set a $6.00 price objective on shares of Gain Therapeutics in a report on Wednesday, March 27th.

Gain Therapeutics Stock Down 1.3 %

Shares of NASDAQ:GANX opened at $3.03 on Tuesday. Gain Therapeutics has a 1 year low of $2.00 and a 1 year high of $5.65. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.59 and a quick ratio of 3.59. The business’s 50-day moving average is $3.97 and its 200-day moving average is $3.44. The company has a market capitalization of $49.15 million, a price-to-earnings ratio of -1.77 and a beta of 0.43.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. Equities research analysts predict that Gain Therapeutics will post -1.22 earnings per share for the current year.

Insider Buying and Selling

In other Gain Therapeutics news, Director Jeffrey Scott Riley purchased 30,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was acquired at an average price of $3.86 per share, for a total transaction of $115,800.00. Following the purchase, the director now owns 30,000 shares of the company’s stock, valued at approximately $115,800. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 11.00% of the stock is owned by company insiders.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.